Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 6, 2004, Pages 1505-1515

  Jiang, Weiqin ^a   Alford, Vernon C ^a   Qiu, Yuhong ^a   Bhattacharjee, Sheela ^a   John, T Matthew ^a   Haynes Johnson, Donna ^a   Kraft, Patricia J ^a   Lundeen, Scott G ^a   Sui, Zhihua ^a  

^a Drug Discovery Raritan   (United States)

Author keywords

Carboline; MED (male erectile dysfunction); PDE5 inhibitor; Pyrroloquinolone

Indexed keywords

11 (2,3 DIHYDROBENZOFURAN 5 YL) 7 METHYL 5,5,A,8,9,11,12 HEXAHYDRO 7H 7,10A,12 TRIAZACYCLOHEPTA[B]FLUORENE 6,10 DIONE; 11 (2,3 DIHYDROBENZOFURAN 6 YL) 3 METHYL 2,3,4A,11 TETRAHYDRO 10H 3,10,11A TRIAZABENZO[B]FLUORENE 1,4,5 TRIONE; 11 (BENZO[1,3]DIOXOL 5 YL) 3 BENZYL 2,3,4A,11 TETRAHYDRO 10H 3,10,11A TRIAZABENZO[B]FLUORENE 1,4,5 TRIONE; 11 (BENZO[1,3]DIOXOL 5 YL) 3 METHYL 2,3,4A,11 TETRAHYDRO 10H 3,10,11A TRIAZABENZO[B]FLUORENE 1,4,5 TRIONE; 11 (BENZO[1,3]DIOXOL 5 YL) 3 PYRIDIN 2 YLMETHYL 2,3,4A,11 TETRAHYDRO 10H 3,10,11A TRIAZABENZO[B]FLUORENE 1,4,5 TRIONE; BETA CARBOLINE DERIVATIVE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V INHIBITOR; QUINOLONE DERIVATIVE; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SYNTHESIS; ERECTILE DYSFUNCTION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; IN VIVO STUDY; NONHUMAN; PRESSURE; RAT; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; DOGS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1542301645     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2003.12.044     Document Type: Article

References (36)

1. Corbin J.D., Francis S.H. J. Biol. Chem. 274:1999;13729.
2. Soderling S.H., Beavo J.A. Curr. Opin. Cell Biol. 12:2000;174.
3. Francis S.H., Turko I.V., Corbin J.D. Prog. Nucleic Acid Res. Mol. Biol. 65:2001;1.
4. For MED, see: Lue T.F. Engl. J. Med. 342:2000;1802.
5. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. J. Urol. 151:1994;54.
6. For Viagra® (sildenafil), see: Brook G. Drugs Today. 26:2000;125. and references therein.
7. For Cialis® (tadalafil), see: Drugs Future. 26(2):2001;141. and references therein.
8. For discovery of tadalafil, see: Daugan A., Grondin P., Ruault C., Gouville A.-C.L.M., Coste H., Kirilovsky J., Hyafil F., Labaudiniere R. J. Med. Chem. 46:2003;4525.
9. Daugan A., Grondin P., Ruault C., Gouville A.-C.L.M., Coste H., Linget J.M., Kirilovsky J., Hyafil F., Labaudiniere R. J. Med. Chem. 46:2003;4533.
10. For Levitra® (vardenafil), see: Drugs Future. 26(1):2001;15. and references therein.
11. For comparison of the three launched PDE5 inhibitors, see: Gresser U., Gleiter C.H. Eur. J. Med. Res. 7:2002;435.
12. Sui Z. Expert Opin. Therap. Pat. 13:2003;1373.
13. Sorbera L.A., Martin L., Leeson P.A., Castaner J. Drugs Future. 26:2001;15.
14. Wang H., Ganesan A. J. Org. Chem. 65:2000;4685.
15. Wang H., Ganesan A. Org. Lett. 1:1999;1647.
16. Wang H., Usui T., Osada H., Ganesan A. J. Med. Chem. 43:2000;1577.
17. Nussbaum F., Danishefsky S. J. Angew, Chem. Int. Eng. Ed. 39:2000;2175.
18. Nakagawa M., Fukushima H., Kawate T., Hongu M., Une T., Kodato S., Taniguchi M., Hino T. Chem. Pharm. Bull. 37:1989;23.
19. Daugan, A. C.-M. JP 199509221, US 6140329, WO 9703675.
20. Sui Z., Macielag M.J., Guan J., Jiang W., Lanter J.C. PCT Int. Appl. 2001;WO0187882.
21. Sui Z., Macielag M.J. PCT Appl. 2001;WO 0187038.
22. Jiang W., Sui Z. PCT Int. Appl. 2003;WO 0342213.
23. Sui Z., Guan J., Macielag M.J., Jiang W., Qiu Y., Kraft P., Bhattacharjee S., John T.M., Craig E., Haynes-Johnson D., Clancy J. Bioorg. Med. Chem. Lett. 13:2003;761.
24. Sui Z., Guan J., Macielag M.J., Jiang W., Zhang S., Qiu Y., Kraft P., Bhattacharjee S., John T.M., Craig E., Haynes-Johnson D., Clancy J. J. Med. Chem. 45:2002;4094.
25. Jiang W., Sui Z., Macielag M.J., Walsh S.P., Fiordeliso J.J., Lanter J.C., Guan J., Qiu Y., Kraft P., Bhattacharjee S., Craig E., Haynes-Johnson D., John T.M., Clancy J. J. Med. Chem. 46:2003;441.
26. Jiang W., Sui Z., Chen X. Tet. Lett. 43:2002;8941.
27. Jiang W., Zhang X., Sui Z. Org. Lett. 5:2003;43.
28. Zhang X., Jiang W., Sui Z. J. Org. Chem. 68:2003;4523.
29. Lanter, J. C.; Walsh, S. P.; Sui, Z.; Macielag, M. J.; Jiang, W.; Fiordeliso, J. J.; Guan, J.; Qiu, Y.; Kraft, P.; Lombardi, E.; John, T. M.; Clancy, J. J. Med. Chem. in press.
30. Qiu Y., Bhattacharjee S., Kraft P., John T.M., Craig E., Haynes-Johnson D., Guan J., Jiang W., Macielag M., Sui Z., Clancy J., Lundeen S. Euro. J. Pharmacol. 472:2003;73.
31. Winterfeldt E. Liebigs Ann. Chem. 745:1971;23.
32. Warneke J., Winterfeldt E. Chem. Ber. 105:1972;2120.
33. Boch M., Korth T., Nelke J.M., Pike D., Radunz H., Winterfeldt E. Chem. Ber. 105:1972;2126.
34. Carniaux J.-F., Kan-Fan C., Royer J., Husson H.-P. Tetrahedron Lett. 38:1997;2997.
35. Ungemach F., Soerens D., Weber R., DiPierro M., Campos O., Mokry P., Cook J.M., Silverton J.V. J. Am. Chem. Soc. 102:1980;6979.
36. Bailey P.D., Hollinshead S.P. Heterocycles. 26:1987;389.